GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » PS Ratio

Abeona Therapeutics (Abeona Therapeutics) PS Ratio

: 37.94 (As of Today)
View and export this data going back to 1980. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Abeona Therapeutics's share price is $7.36. Abeona Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.19. Hence, Abeona Therapeutics's PS Ratio for today is 37.94.

Warning Sign:

Abeona Therapeutics Inc stock PS Ratio (=46.16) is close to 3-year high of 46.16

The historical rank and industry rank for Abeona Therapeutics's PS Ratio or its related term are showing as below:

ABEO' s PS Ratio Range Over the Past 10 Years
Min: 2.13   Med: 24.85   Max: 854.32
Current: 37.91

During the past 13 years, Abeona Therapeutics's highest PS Ratio was 854.32. The lowest was 2.13. And the median was 24.85.

ABEO's PS Ratio is ranked worse than
76.44% of 993 companies
in the Biotechnology industry
Industry Median: 8.75 vs ABEO: 37.91

Abeona Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.19.

Warning Sign:

Abeona Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Abeona Therapeutics was -8.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -60.70% per year.

During the past 13 years, Abeona Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 236.90% per year. The lowest was -84.00% per year. And the median was 21.80% per year.

Back to Basics: PS Ratio


Abeona Therapeutics PS Ratio Historical Data

The historical data trend for Abeona Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 14.55 11.06 17.11 30.55

Abeona Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.11 16.02 20.35 21.26 30.55

Competitive Comparison

For the Biotechnology subindustry, Abeona Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's PS Ratio falls into.



Abeona Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Abeona Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=7.36/0.194
=37.94

Abeona Therapeutics's Share Price of today is $7.36.
Abeona Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Abeona Therapeutics  (NAS:ABEO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Abeona Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (Abeona Therapeutics) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219

Abeona Therapeutics (Abeona Therapeutics) Headlines